By: Norton Healthcare April 17, 2026
By: Norton Healthcare
April 17, 2026
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma